In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile
暂无分享,去创建一个
Cheng Cheng | Ching-Hon Pui | Deqing Pei | Wenjian Yang | M. Relling | Cheng Cheng | C. Pui | W. Evans | Wenjian Yang | J. Panetta | D. Pei | N. Pottier | L. Kager | M. Cheok | M. Sorich | Mary V Relling | William E Evans | G. Stocco | Michael J Sorich | John C Panetta | Nicolas Pottier | Leo Kager | Gabriele Stocco | Meyling H Cheok | Deqing Pei
[1] J. Downing,et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. , 2007, Blood.
[2] J. Bertino,et al. Reduced Folate Carrier and Dihydrofolate Reductase Expression in Acute Lymphocytic Leukemia May Predict Outcome: A Children's Cancer Group Study , 2003, Journal of pediatric hematology/oncology.
[3] M. Relling,et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. , 1996, The Journal of clinical investigation.
[4] M. Relling,et al. Moving towards individualized medicine with pharmacogenomics , 2004, Nature.
[5] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[6] M. Cheok,et al. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy , 2006, Nature Reviews Cancer.
[7] F. Behm,et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital , 2000, Leukemia.
[8] H. Handa,et al. A New Mechanism of Methotrexate Action Revealed by Target Screening with Affinity Beads , 2006, Molecular Pharmacology.
[9] M. Relling,et al. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. , 1994, Blood.
[10] Thomas Flohr,et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. , 2005, Blood.
[11] G. Peters,et al. Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay , 1999 .
[12] J. Shuster,et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. , 1990, Blood.
[13] Jelle J. Goeman,et al. A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..
[14] L. Penland,et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.
[15] M. Relling,et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. , 2002, Blood.
[16] M. Kuwano,et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. , 2002, Cancer research.
[17] E. Cook,et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. , 2004, Blood.
[18] T. Golub,et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.
[19] J. McGuire. Enzymatic synthesis of folylpolyglutamates , 1980 .
[21] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[22] Ching-Hon Pui,et al. Acute lymphoblastic leukemia. , 2004, The New England journal of medicine.
[23] Bertino,et al. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. , 2001, Haematologica.
[24] G. Curt,et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? , 1985, The Journal of clinical investigation.
[25] E. De Clercq,et al. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. , 1999, Biochemical pharmacology.
[26] J. Bertino,et al. Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. , 1980, The Journal of biological chemistry.
[27] Debabrata Banerjee,et al. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. , 2002, Biochimica et biophysica acta.
[28] J. Downing,et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. , 2005, The Journal of clinical investigation.
[29] C. Pui,et al. Biology and Clinical Significance of Cytogenetic Abnormalities in Childhood Acute Lymphoblastic Leukemia , 1990 .
[30] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[31] K. Kohn. Regulatory genes and drug sensitivity. , 1996, Journal of the National Cancer Institute.
[32] D. Goldman,et al. Membrane transport of folates. , 2003, Vitamins and hormones.
[33] J. Downing,et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.
[34] J. Downing,et al. Results of therapy for acute lymphoblastic leukemia in black and white children. , 2003, JAMA.
[35] M. Relling,et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. , 2003, The New England journal of medicine.
[36] M. Waltham,et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. , 1996, The New England journal of medicine.
[37] M. Relling,et al. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] C. Pui,et al. Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.
[39] John D. Storey,et al. Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[40] T. Poggio,et al. Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[42] G. Peters,et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. , 1999, Cancer research.
[43] M. Relling,et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.
[44] T. Kute,et al. Proliferation-dependent cytotoxicity of methotrexate in murine L5178Y leukemia. , 1988, Cancer research.
[45] S. P. Fodor,et al. High density synthetic oligonucleotide arrays , 1999, Nature Genetics.
[46] M. Relling,et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. , 1994, The Journal of clinical investigation.
[47] J. Downing,et al. Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.
[48] A. Veerman,et al. Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia , 2003, British Journal of Cancer.
[49] Cheng Cheng,et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.
[50] P. A. Rea,et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. , 2001, Cancer research.